From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial

Last Updated: Thursday, September 19, 2024

Although Choosing Wisely recommendations advocate against the use of sentinel lymph node biopsy (SLNB) use in older women with early-stage, clinically node-negative, and HR+ HER2- breast cancer, it is a practice that is still widely used. To combat this overuse, investigators used an electronic health record–based nudge intervention that targeted surgeons in their first outpatient visit with patients in this population. During the nudge intervention period, unadjusted rates of SLNB decreased by 23.1 percentage points compared with rates during the control period. The investigators concluded that the nudge intervention was easily implementable and could help decrease low-value care both in this and other settings.  

JAMA Surgery
Advertisement
News & Literature Highlights

International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

American Journal of Clinical Oncology

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Frontiers in Immunology

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

Future Oncology

The NEOLETRIB trial: Neoadjuvant treatment with letrozole and ribociclib in ER-positive, HER2-negative breast cancer

JAMA Surgery

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial

Advertisement
Advertisement